Trinity Biotech Plc (TRIB)

$2.86

-0.13

(-4.35%)▲

Market is closed - opens 7 PM, 29 Jul 2024

Performance

  • $2.80
    $2.97
    $2.86
    downward going graph

    2.08%

    Downside

    Day's Volatility :5.7%

    Upside

    3.7%

    downward going graph
  • $1.49
    $5.10
    $2.86
    downward going graph

    47.9%

    Downside

    52 Weeks Volatility :70.78%

    Upside

    43.92%

    downward going graph

Returns

PeriodTrinity Biotech PlcIndex (Russel 2000)
3 Months
63.39%
0.0%
6 Months
42.38%
0.0%
1 Year
-41.94%
0.0%
3 Years
-70.4%
-20.2%

Highlights

Market Capitalization
29.7M
Book Value
- $2.58
Earnings Per Share (EPS)
4.25
PE Ratio
0.74
PEG Ratio
1.3
Wall Street Target Price
3.0
Profit Margin
-37.96%
Operating Margin TTM
-20.68%
Return On Assets TTM
-10.47%
Return On Equity TTM
-1913.45%
Revenue TTM
56.7M
Revenue Per Share TTM
7.12
Quarterly Revenue Growth YOY
-0.8%
Gross Profit TTM
38.1M
EBITDA
-13.3M
Diluted Eps TTM
4.25
Quarterly Earnings Growth YOY
-0.77
EPS Estimate Current Year
0.0
EPS Estimate Next Year
0.0
EPS Estimate Current Quarter
0.0
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Buy
    85%Buy
    14%Hold
    0
    0%Sell
Based on 7 Wall street analysts offering stock ratings for Trinity Biotech Plc(by analysts ranked 0 to 5 stars)
Based on 7 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
6
6
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 4.9%

Current $2.86
Target $3.00

Company Financials

FY18Y/Y Change
Revenue
97.0M
↓ 2.12%
Net Income
2.4M
↓ 105.93%
Net Profit Margin
2.46%
↑ 43.08%
FY19Y/Y Change
Revenue
90.4M
↓ 6.8%
Net Income
-4.1M
↓ 270.13%
Net Profit Margin
-4.5%
↓ 6.96%
FY20Y/Y Change
Revenue
102.0M
↑ 12.77%
Net Income
-6.0M
↑ 47.88%
Net Profit Margin
-5.9%
↓ 1.4%
FY21Y/Y Change
Revenue
93.0M
↓ 8.84%
Net Income
875.0K
↓ 114.55%
Net Profit Margin
0.94%
↑ 6.84%
FY22Y/Y Change
Revenue
74.8M
↓ 19.56%
Net Income
-41.0M
↓ 4785.94%
Net Profit Margin
-54.83%
↓ 55.77%
FY23Y/Y Change
Revenue
56.8M
↓ 24.0%
Net Income
-24.0M
↓ 41.42%
Net Profit Margin
-42.26%
↑ 12.57%
Q4 FY22Q/Q Change
Revenue
14.8M
↓ 17.78%
Net Income
-6.3M
↓ 37.43%
Net Profit Margin
-42.52%
↑ 13.35%
Q1 FY23Q/Q Change
Revenue
18.0M
↑ 21.63%
Net Income
-10.1M
↑ 59.81%
Net Profit Margin
-55.87%
↓ 13.35%
Q2 FY23Q/Q Change
Revenue
13.9M
↓ 22.94%
Net Income
-6.0M
↓ 40.57%
Net Profit Margin
-43.09%
↑ 12.78%
Q3 FY23Q/Q Change
Revenue
14.7M
↑ 5.61%
Net Income
-6.7M
↑ 12.24%
Net Profit Margin
-45.79%
↓ 2.7%
Q4 FY23Q/Q Change
Revenue
13.4M
↓ 8.51%
Net Income
-5.5M
↓ 18.14%
Net Profit Margin
-40.97%
↑ 4.82%
Q1 FY24Q/Q Change
Revenue
13.4M
↑ 0.0%
Net Income
-5.5M
↑ 0.0%
Net Profit Margin
-40.97%
↑ 0.0%
FY18Y/Y Change
Total Assets
151.2M
↓ 21.48%
Total Liabilities
107.2M
↓ 15.88%
FY19Y/Y Change
Total Assets
131.1M
↓ 13.33%
Total Liabilities
126.4M
↑ 17.89%
FY20Y/Y Change
Total Assets
130.4M
↓ 0.51%
Total Liabilities
132.6M
↑ 4.95%
FY21Y/Y Change
Total Assets
118.9M
↓ 8.82%
Total Liabilities
119.2M
↓ 10.11%
FY22Y/Y Change
Total Assets
92.1M
↓ 22.53%
Total Liabilities
94.3M
↓ 20.92%
FY23Y/Y Change
Total Assets
59.4M
↓ 35.47%
Total Liabilities
83.4M
↓ 11.56%
Q4 FY22Q/Q Change
Total Assets
91.2M
↓ 1.03%
Total Liabilities
97.8M
↑ 3.71%
Q1 FY23Q/Q Change
Total Assets
92.1M
↑ 1.04%
Total Liabilities
94.3M
↓ 3.57%
Q2 FY23Q/Q Change
Total Assets
72.0M
↓ 21.84%
Total Liabilities
83.4M
↓ 11.57%
Q3 FY23Q/Q Change
Total Assets
63.6M
↓ 11.66%
Total Liabilities
81.1M
↓ 2.74%
Q4 FY23Q/Q Change
Total Assets
59.4M
↓ 6.54%
Total Liabilities
83.4M
↑ 2.84%
Q1 FY24Q/Q Change
Total Assets
59.4M
↑ 0.0%
Total Liabilities
83.4M
↑ 0.0%
FY18Y/Y Change
Operating Cash Flow
6.9M
↓ 42.74%
Investing Cash Flow
-17.4M
↑ 7.48%
Financing Cash Flow
-17.0M
↑ 11.37%
FY19Y/Y Change
Operating Cash Flow
5.5M
↓ 21.07%
Investing Cash Flow
-11.9M
↓ 31.84%
Financing Cash Flow
-4.0M
↓ 76.47%
FY20Y/Y Change
Operating Cash Flow
23.8M
↑ 333.96%
Investing Cash Flow
-10.2M
↓ 13.96%
Financing Cash Flow
-2.7M
↓ 32.03%
FY21Y/Y Change
Operating Cash Flow
13.2M
↓ 44.27%
Investing Cash Flow
-7.1M
↓ 30.68%
Financing Cash Flow
-6.0M
↑ 121.61%
Q4 FY22Q/Q Change
Operating Cash Flow
-2.7M
↓ 219.47%
Investing Cash Flow
-1.3M
↑ 0.38%
Financing Cash Flow
1.6M
↓ 187.15%
Q1 FY23Q/Q Change
Operating Cash Flow
2.3M
↓ 183.7%
Investing Cash Flow
-1.3M
↑ 0.0%
Financing Cash Flow
-1.8M
↓ 214.74%
Q2 FY23Q/Q Change
Operating Cash Flow
-4.4M
↓ 294.2%
Investing Cash Flow
27.9M
↓ 2196.46%
Financing Cash Flow
-13.5M
↑ 629.21%

Technicals Summary

Sell

Neutral

Buy

Trinity Biotech Plc is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Trinity Biotech Plc
Trinity Biotech Plc
45.15%
42.38%
-41.94%
-70.4%
-72.82%
Stryker Corporation
Stryker Corporation
-3.84%
5.16%
12.86%
24.25%
52.69%
Boston Scientific Corp.
Boston Scientific Corp.
-3.68%
21.48%
41.72%
68.89%
76.47%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
-34.8%
-18.49%
-34.85%
-45.17%
-15.86%
Abbott Laboratories
Abbott Laboratories
1.03%
-5.4%
-7.12%
-11.35%
20.75%
Medtronic Plc
Medtronic Plc
-1.99%
-9.34%
-13.21%
-38.74%
-23.49%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Trinity Biotech Plc
Trinity Biotech Plc
0.74
0.74
1.3
0.0
-19.13
-0.1
NA
-2.58
Stryker Corporation
Stryker Corporation
38.91
38.91
2.92
11.95
0.19
0.07
0.01
50.33
Boston Scientific Corp.
Boston Scientific Corp.
63.22
63.22
1.8
2.37
0.09
0.05
NA
13.16
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
36.4
36.4
5.19
2.76
0.22
0.12
NA
12.35
Abbott Laboratories
Abbott Laboratories
33.84
33.84
5.99
4.66
0.15
0.06
0.02
22.31
Medtronic Plc
Medtronic Plc
28.97
28.97
1.52
5.2
0.07
0.04
0.04
38.29
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Trinity Biotech Plc
Trinity Biotech Plc
Buy
$29.7M
-72.82%
0.74
-37.96%
Stryker Corporation
Stryker Corporation
Buy
$129.7B
52.69%
38.91
16.03%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$114.3B
76.47%
63.22
12.05%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
Buy
$52.4B
-15.86%
36.4
23.74%
Abbott Laboratories
Abbott Laboratories
Buy
$186.6B
20.75%
33.84
13.65%
Medtronic Plc
Medtronic Plc
Buy
$102.5B
-23.49%
28.97
11.36%

Insights on Trinity Biotech Plc

  • Decreasing Revenue

    Revenue is down for the last 3 quarters, 14.67M → 13.42M (in $), with an average decrease of 4.3% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 3 quarters, -6.72M → -5.50M (in $), with an average increase of 11.1% per quarter

  • Vs BSX

    In the last 1 year, Boston Scientific Corp. has given 41.7% return, outperforming this stock by 83.6%

  • Vs BSX

    In the last 3 years, Boston Scientific Corp. has given 68.9% return, outperforming this stock by 139.3%

Institutional Holdings

  • Perceptive Advisors LLC

    19.02%

  • Hunter Associates Inc.

    3.36%

  • Renaissance Technologies Corp

    2.82%

  • Stonehill Capital Management LLC

    2.62%

  • Acadian Asset Management LLC

    1.23%

  • Whitefort Capital Management, LP.

    0.87%

Company Information

since its formation in 1992, trinity biotech has actively pursued the aim of becoming a leading player in the international diagnostics industry. through a combination of sustained, organic growth and an acquisition-led strategy, the company has assembled an impressive product portfolio and achieved the highest standards of excellence in developing, manufacturing and marketing diagnostic products. the test kits manufactured by trinity biotech are used in the clinical laboratory and point-of-care segments of the diagnostic market to detect infectious diseases, sexually transmitted diseases, autoimmune and haemoglobin disorders, and detect, monitor and control diabetes. the company is also a significant provider of raw materials to the life sciences industry. trinity biotech, which has its headquarters in ireland, employs in excess of 350 people and markets its portfolio of over 400 products to customers in 80 countries around the world. it reaches this worldwide market by combining the

Organization
Trinity Biotech Plc
Employees
380
CEO
Mr. John Gillard
Industry
Health Technology

Discover More

FAQs